Innovating Antibodies, Improving Lives

Investor Presentation
November 2019

Genmab

Forward Looking Statement

This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Building a Business that Transforms Cancer Treatment

Our Core Purpose, Strategy & Vision

Genmab

Core Purpose

To improve the lives of patients by creating & developing innovative antibody products

Strategy

- Turn science into medicine
- Build a profitable & successful biotech
- Focus on core competence

Vision

By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks off antibodies

Innovation Powerhouse

The Genmab Difference

Proprietary technologies allow us to build a world-class pipeline

Match in-house expertise with strategic partnerships

Strong pipeline of 1st – in-class / best-in-class products

Deep insight into antibody biology & disease targets

Creating value, transforming cancer treatment

Track Record & Growth: 20 Years of Achievement

Revenue:
Expanding Top Line
2003[1]: $10M
2018: $455M

Operating Result:
Sustainable Profits
2013[1]: $10M
2018: $208M

Dual-listed in US & DK with 2019 US IPO:
Largest of IPO ADSs by a EU Healthcare Co.; 2nd largest US IPO ever for biotech

Cumulative INDs from 1999
1999[1]: 1
To date: 33

Genmab Created Products in Ongoing Clinical Trials
2000: 1
2019: 18

Genmab Created Products on the Market
DARZALEX®
Arzerra®

Our Own[2] Products in Clinical Development: 2017: 2[3] | 2018: 4 | **2019: 7[4]**

All amounts in USD millions. USD 1 = DKK 6.6446, [1]First year for which the category applies, [2]We consider products for which we retain at least 50% of the rights as "our own" proprietary products [3]As of 1/1/17, [4]Projected by end of 2019

Solid Foundation Built on Differentiated Pipeline

Foundational Products

- DARZALEX®
- Arzerra®
- Ofatumumab [RMS]

Our Own Clinical Pipeline

- Tisotumab Vedotin[1]
- Enapotamab Vedotin
- HexaBody®-DR5/DR5
- DuoBody®-CD3xCD20
- DuoBody-PD-L1x4-1BB[2]
- DuoBody-CD40x4-1BB[2]

- *2019 Projected IND/CTA:* DuoHexaBody®-CD37[3]

Partner Programs

10 product candidates in clinical development w/ partners incl. 6 DuoBody products with Janssen

Technologies & Pre-Clinical

- DuoBody
- HexaBody
- HexElect®
- DuoHexaBody®
- Rich Pre-Clinical Pipeline

Solid Financial Base Significant Potential

Potential First-in-Class / Best-in-Class

Additional Shots on Goal

R&D Engine

[1]In partnership with Seattle Genetics; [2]In partnership with BioNTech; [3]Expected

Daratumumab (Marketed as Darzalex)

Reshaping Treatment of Multiple Myeloma Across All Lines of Therapy

First-in-class CD38 antibody in development to treat cancer

Collaboration with Janssen: Genmab entitled to tiered royalty of 12-20% of net sales and up to $444M in certain remaining milestone payments

Approved in certain territories for various multiple myeloma (MM) indications[1]

2018 WW net sales by J&J: $2,025M

9 mo 2019 WW net sales by J&J: $2,168M

Multiple Phase III studies ongoing in MM and amyloidosis, and for a subcutaneous formulation

Daratumumab Development Covering All Stages of Multiple Myeloma – Key Ongoing Trials

Disease Stage	Therapy	No. Pts*	Development Phase
High Risk Smoldering	Subcutaneous	360	✓ AQUILA
	Monotherapy	123	✓ CENTAURUS
Front line (transplant & non-transplant)	Dara + VMP	706	✓ ALCYONE
	Dara + VMP (Asia Pacific)	210	OCTANS
	Dara + Rd	737	✓ MAIA
	Dara + VRd	360	✓ CEPHEUS
	Dara + VTd	1,080	✓ CASSIOPEIA
	Dara + VRd	690	PERSEUS
	Dara + R (maintenance)	214	AURIGA
	Dara + VRd	224	✓ GRIFFIN
Relapsed or Refractory	Dara + Vd (China)	210	✓ LEPUS
	Dara + Kd	466	✓ CANDOR
	Dara + Pom + d	302	✓ APOLLO
	Subcutaneous vs IV	521	✓ COLUMBA
	Dara + combinations	>600	NINLARO® (Ph II), Venclexta® (Ph II), Selinexor (Ph I/II)
	Dara + [illegible]	>70	Cyburn® (Ph I/II)

Development Phase: Pre-Clinical | I | I/II | II | III

✓ Fully recruited Maintenance integrated into some study protocols *Number of pts is for all trial arms, per clinicaltrials.gov V = Velcade®, MP = melphalan-prednisone , T = thalidomide d= dexamethasone [illegible] Kyprolis®, Pom = Pomalyst®

Daratumumab Development: Beyond Multiple Myeloma

Disease	Therapy	No. Pts*	Development Phase
AL Amyloidosis	Dara + CyBorD	370	✓ ANDROMEDA
ALL	Dara + SoC chemo	69	DELPHINUS
NKTCL (nasal type)	Dara monotherapy	32	✓ VOLANS

Development Phase: Pre-Clinical | I | I/II | II | III

CyBorD = cyclophosphamide, bortezomib and dexamethasone

[1]Approved in combination with other therapies for frontline multiple myeloma in U.S. and EU, in combination with other therapies in relapsed/refractory multiple myeloma in U.S., EU and Japan; and as monotherapy for heavily pretreated or double-refractory multiple myeloma in U.S. and EU. See local country prescribing information for precise indications

Daratumumab Efficacy in Newly Diagnosed Multiple Myeloma

Phase III MAIA Trial (D+Rd): ASH Dec 2018



In D-Rd arm:

- 44% reduction risk of disease progression or death in patients receiving D-Rd
- Median PFS not reached
- **>3-fold higher MRD-negative rate**

✓ **2019 – Filing & FDA Approval**

D = daratumumab
R = lenalidomide
d = dexamethasone
PFS = progression free survival
MRD – minimal residual disease

Daratumumab: Proving to be the Critical Driver Across Different Combinations & Treatment Lines



[1]Includes CR + sCR in daratumumab arm versus control arm. CR = complete response, which refers to patients who achieve negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and achieve less than or equal to 5% plasma cells in the bone marrow; sCR = stringent complete response, which is tested using more sensitive methods to detect monoclonal plasma cells, and is defined as patients who achieve CR and exhibit a normal free light chain ratio in the serum and absence of clonal cells in the bone marrow determined by either immunofluorescence or immunohistochemistry; in each case as defined by the International Myeloma Working Group, or IMWG. [2]MRD = minimal residual disease, which refers to the persistence of small numbers of myeloma cells that remain after therapy and contribute to relapse and disease progression; MRD negativity is defined as the absence of aberrant clonal plasma cells on bone marrow aspirate, ruled out by an assay with a minimum sensitivity of one in 105 nucleated cells or higher; MRD-neg rate refers to the proportion of patients with negative MRD test results, tested at 10-5 sensitivity, or one in 105 cells, from the time of suspected CR or sCR, in the case of the MAIA, POLLUX and CASTOR studies and confirmed CR/sCR in the case of the ALCYONE study, and tested periodically for a certain period after dosing. [3]Risk reduction in disease progression or death versus control arm. PFS = progression free survival.

Ofatumumab (OMB 157)

Potential in Relapsing Multiple Sclerosis

- Human mAb targeting CD20 – well validated target: Collaboration with Novartis
- In two clinical Phase III studies (ASCLEPIOS I & II) in relapsing multiple sclerosis (RMS)
- ASCLEPIOS I & II: Subcutaneous dosing 20mg every 4 weeks
- Positive data from ASCLEPIOS studies announced end of August – met primary & secondary endpoints
- Novartis plans to initiate submissions to health authorities by end of 2019
- Genmab entitled to 10% royalty payment of net sales for non-cancer treatments

Ofatumumab Development: Key Ongoing Trials

✓ Fully recruited

*Pts who have completed a selected Novartis MS study which dosed ofatumumab 20 mg subcutaneous every 4 weeks

Also marketed as Arzerra in certain territories for various CLL indications[1, 2]

- Genmab entitled to 20% royalty payment of net oncology sales: 2018 net sales of Arzerra by Novartis were $26M

[1]See local country prescribing information for precise indications,[2]On January 22, 2018, Novartis announced that it intends to transition Arzerra in non-U.S. markets from commercial availability to limited access programs or alternative solutions for approved CLL indications where applicable and allowed by local regulators. We expect Arzerra to remain commercially available for approved CLL indications in the United States and Japan.

Tisotumab Vedotin

Genmab's Most Advanced Asset with Potential in Solid Tumors

Fully human Antibody-drug conjugate (ADC) targeting Tissue Factor (TF) in development to treat solid tumors

License and collaboration agreement with Seattle Genetics 50:50

Phase II potentially registrational study (innovaTV 204) in cervical cancer ongoing after encouraging Phase I/II data (innovaTV 201)

Phase II clinical studies in ovarian and solid tumor basket studies; expanding development w/ additional studies planned

Tisotumab Vedotin Development: Ongoing Trials

Disease	Stage	Development Phase: Pre-Clinical / I / I/II / II / III
Cervical cancer	Recurrent or metastatic	✓ innovaTV 204
	Recurrent	innovaTV 205
	Japan	innovaTV 206
Ovarian cancer	Platinum resistant	innovaTV 208
Solid tumors	Locally advanced or metastatic	innovaTV 207
	Locally advanced or metastatic	✓ innovaTV 201

✓ Fully recruited

Genmab & SeattleGenetics®

Tisotumab Vedotin in Cervical Cancer

Designed to Address a High Unmet Medical Need

Recurrent or metastatic cervical cancer

- Poor prognosis for advanced / recurrent cervical cancer
  - Response rates to standard therapies generally <15%
  - Median overall survival 6-8 months
- Data on ORR and survival after progression on 1L bevacizumab + doublet chemotherapy are limited

Conclusions*

- Manageable adverse events and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer
- IRC-assessed overall response rate of 35% (confirmed and unconfirmed) and confirmed ORR was 22%, with a median DOR of 6.0 months and a 6-month PFS of 40%

Encouraging Antitumor Activity Observed*

	N=55	
	IRC-Assessed[a]	INV-Assessed
ORR confirmed + unconfirmed (95% CI), %	35 (22–49)	31 (19–45)
ORR confirmed (95% CI), %	22 (12–35)	24 (13–37)
CR, n (%)	1 (2)	0
PR, n (%)	11 (20)	13 (24)
SD, n (%)	19 (35)	21 (38)
PD, n (%)	17 (31)	17 (31)
Not evaluable,[b] n (%)	5 (9)	4 (7)
DCR confirmed (95% CI), %	56 (42–70)	62 (48–75)
Median DOR (range), months	6.0 (1.0+–9.7)	4.2 (1.0+–9.7)
Median PFS (95% CI), months	4.1 (1.7–6.7)	4.2 (2.1–5.3)
6-month PFS rate (95% CI), %	40 (24–55)	29 (17–43)

*Data from innovaTV 201 study, Hong DS, et al. Tisotumab Vedotin in Cervical Cancer, SGO March 16-19, 2019

Tisotumab Vedotin

Clinical Development: Ongoing Ph II Studies

Ph II, recurrent or metastatic cervical cancer (innovaTV 204)

- Potentially registrational Up to 100 pts
- Single arm, monotherapy
- Primary endpoint: confirmed ORR
- Secondary endpoints: duration of response, PFS, OS*

(innovaTV 206) study in Japanese population

Ph II, recurrent or metastatic cervical cancer in combo's (innovaTV 205)

- Phase I/II study of tisotumab vedotin in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer
- Primary endpoint: ORR
- Secondary endpoints: Safety, duration of response, time to response, PFS, OS

Ph II, solid tumors (innovaTV 207)

- Basket study
- Up to 200 pts
- Single arm, monotherapy
- Primary endpoint: ORR
- Secondary endpoints: Safety, disease control rate, duration of response, time to response, PFS, OS

Ph II, ovarian cancer (innovaTV 208)

- Ovarian cancer, fallopian tube cancer, peritoneal cancer
- Up to 142 pts, incl 12 pt safety run-in
- Monotherapy:
- 2 schedules: every 3 weeks and dose dense
- Primary endpoints: Safety & ORR

*Text in box related to innovaTV 204

Enapotamab Vedotin (HuMax-Axl-ADC)

Potential in Solid Tumors

- Fully human ADC, targets tumor-associated AXL
- AXL over-expressed on many resistant tumors
- Ph I/II study ongoing in multiple solid tumors: expansion cohorts recruiting
- ADC technology licensed from Seattle Genetics in September 2014 for an up-front fee of $11M
- Seattle Genetics eligible for milestone payments and royalties, Genmab retains full control of development & commercialization

Enapotamab Vedotin Development: Ongoing Trial

HexaBody-DR5/DR5 (GEN1029)

First HexaBody in Clinical Development

- Targets two distinct epitopes on death receptor 5 (DR5), cell surface receptor that mediates programmed cell death
- Proprietary HexaBody technology: first HexaBody product in the clinic
- 100% Genmab owned
- Phase I/II study ongoing in multiple solid tumors
- March 2015, DR5 antibodies and associated intellectual property rights acquired from iDD Biotech

HexaBody-DR5/DR5 Development: Ongoing Trial



DuoBody-CD3xCD20 (GEN3013)

Potential for Improved Efficacy & Safety in B-Cell Malignancies

- Simultaneous binding to CD3 on T cells & CD20 on B cells observed in preclinical studies
- Proprietary DuoBody Technology: first Genmab-owned DuoBody product in clinic
- 100% Genmab owned
- Differentiated subcutaneous formulation
- Phase I/II study with subcutaneous formulation ongoing in B-cell malignancies

DuoBody-CD3xCD20 Development: Ongoing Trial



DuoBody-PD-L1x4-1BB (GEN1046)

Bispecific Antibody with Potential in Solid Tumors

- Bispecific antibody targeting PD-L1 & 4-1BB (CD137)
- Potential to provide Genmab with differentiated PD-L1 product
- 50:50 co-development Genmab and BioNTech
- Combines checkpoint blockade with T cell stimulation
- Phase I/II study ongoing in solid tumors

DuoBody-PD-L1x4-1BB Development: Ongoing Trial



Genmab & BIONTECH

DuoBody

DuoBody-CD40x4-1BB (GEN1042)

Latest Product Candidate in the Clinic

- Bispecific antibody targeting CD40 & 4-1BB (CD137)
- Potential in solid tumors
- 50:50 co-development Genmab and BioNTech
- Designed to conditionally activate T cells
- Phase I/II study ongoing in solid tumors

DuoBody-CD40x4-1BB Development: Next to the Clinic



Genmab & BIONTECH

DuoBody

DuoHexaBody-CD37: 2019 IND/CTA Target

Building Our Pipeline: Additional Clinical Product Planned

- Based on DuoBody & HexaBody platforms
- Novel target for hematologic malignancies
- 100% Genmab Owned
- Unique mechanism-of-action
- IND/CTA planned for 2019

DuoHexaBody-CD37 Development: IND/CTA Target



Well-Capitalized Biotech – 2019 Guidance

Income Statement	DKKM	~USDM*
Revenue	5,100	761
Operating expenses	(2,750)	(410)
Operating income	2,350	351

Revenue Detail	DKKM	~USDM*	Comments
DARZALEX Royalties	3,000	448	DARZALEX net sales $3.0bn
DARZALEX Milestones	1,675	250	Milestone payment of $150M (DKK 1,000M) from DARZALEX net sales of $3.0bn
All Other	425	63	Includes reimbursement income, DuoBody milestones, Arzerra royalties
Total Revenue	5,100	761	

Expense Detail	DKKM	~USDM*	Comments
Project Investment	1,625	243	Driven by Top 10 Projects (~DKK 1,425 – approx. 50% total expense)
Personnel Costs	625	93	Increase in 2019 by 180 FTEs
Business Support	500	75	Incl. technologies & systems, Commercial & Medical Affairs
Total Operating Expenses	2,750	410	

2019 Guidance – November 6, 2019 / *USD 1.00 = DKK 6.70

Disciplined Investment

Proprietary Portfolio

- 2017: 2 product candidates
- 2018: 4 product candidates
- 2019*: 7 product candidates

Next Gen. Technologies

- DuoBody
- HexaBody
- HexElect
- DuoHexaBody

Strategic Alliances

- Seattle Genetics
- BioNTech
- Immatics
- Tempus
- BliNK



Capabilities

- Expanding: R&D and support
- Adding: Translational Research and Commercial

*Projected to be in clinical development by end of 2019

Key 2019 Priorities

Building a Robust Differentiated Product Portfolio

Priority	✓	Targeted Milestones
Daratumumab	✓ ✓ ✓	» FDA decision on Phase III MAIA multiple myeloma (MM) submission » FDA decision on Phase III CASSIOPEIA MM submission » Phase III COLUMBA MM subcutaneous daratumumab safety & efficacy analysis
Ofatumumab	✓	» Phase III ASCLEPIOS I & II relapsing multiple sclerosis SubQ ofatumumab study completion and reporting
Tisotumab Vedotin	✓	» Phase II innovaTV 204 tisotumab vedotin recurrent / metastatic cervical cancer study enrollment complete by mid year
Innovative pipeline	✓ * 	» Phase II enapotamab vedotin expansion cohort efficacy analysis » Phase I/II HexaBody-DR5/DR5 initial clinical data » Phase I/II DuoBody-CD3xCD20 clinical data dose escalation cohorts » File INDs and/or CTAs for 3 new product candidates

*Initial data now anticipated in 2020. A status update will be available in 2019.

Delivering on Genmab's Promise

Innovating Antibodies, Improving Lives



Creating Substantial Value

Innovating Antibodies, Improving Lives

Appendix

Genmab

Innovation in Action: Solid Track Record

Publicly Listed Company with Large Free Float

Ordinary shares listed on Nasdaq Copenhagen, Denmark

ADSs listed on Nasdaq Global Select, USA

Shares held in countries across the world, including:
- USA
- UK
- DK
- NL

Approx. Market Cap
- DKK 90bn
- USD 13bn

Approx. shares outstanding: 65M

Approx. warrants outstanding: 1.3M (~2%)

Approx. diluted shares: 66M

As of Oct 11, 2019

Innovative Clinical Pipeline

Genmab's Proprietary* Product Candidates

Product	Target	Rights	Disease Indications	Most Advanced Development Phase
				Pre-Clinical / I / I/II / II / III
Tisotumab vedotin	TF	50:50 Genmab / Seattle Genetics	Cervical cancer	I/II
			Ovarian cancer	I/II
			Solid tumors	I/II
Enapotamab vedotin (HuMax-AXL-ADC)	AXL	Genmab	Solid tumors	I
HexaBody-DR5/DR5 (GEN1029)	DR5	Genmab	Solid tumors	I
DuoBody-CD3xCD20 (GEN3013)	CD3, CD20	Genmab	Hematological malignancies	I
DuoBody-PD-L1x4-1BB (GEN1046)	PD-L1, 4-1BB	50:50 Genmab / BioNTech	Solid tumors	I
DuoBody-CD40x4-1BB (GEN1042)	CD40, 4-1BB	50:50 Genmab / BioNTech	Solid tumors	I
CTA/INDs expected in 2019 DuoHexaBody-CD37	CD37	Genmab	Hematologic malignancies	Pre-Clinical

*Certain product candidates in development with partners, as noted.

Partner Programs: Ongoing development

Proposed Label Expansions for Marketed Products

Product	Target	Rights	Disease Indications	Most Advanced Development Phase
				Pre-Clinical / I / I/II / II / III / Launched
Daratumumab	CD38	Janssen (Tiered royalties to Genmab on net global sales)	Multiple myeloma (MM)*	III
			AL Amyloidosis	III
			Non-MM blood cancers	II
Ofatumumab (OMB157)	CD20	Novartis (Royalties to Genmab on net global sales)	Chronic lymphocytic leukemia (CLL)*	III
			Relapsing multiple sclerosis (RMS) (SubQ)	III

*See local country prescribing information for precise indications

Partner programs: Additional Product Candidates in Clinical Development

Product	Target	Partner	Disease Indications	Most Advanced Development Phase
				Pre-Clinical / I / I/II / II / III
Teprotumumab (RV001)	IGF-1R	Horizon Therapeutics (under sublicense from Roche)	Thyroid eye disease	I/II
HuMax-IL8	IL8	BMS	Advanced cancers	I/II
Camidanlumab tesirine (ADCT-301)	CD25	ADC Therapeutics	Relapsed /Refractory Hodgkin Lymphoma	II
			Solid tumors	I
JNJ-61186372	EGFR, cMet	Janssen	Non-small-cell lung cancer (NSCLC)	I/II
JNJ-63709178	CD123, CD3	Janssen	Acute Myeloid Leukemia (AML)	I
JNJ-64007957	BCMA, CD3	Janssen	Relapsed or refractory MM	I
JNJ-64407564	GPRC5D, CD3	Janssen	Relapsed or refractory MM	I
JNJ-67571244	CD33, CD3	Janssen	Relapsed or refractory AML or MDS	I
JNJ-63898081	PSMA, CD3	Janssen	Solid tumors	I
Lu AF82422	alpha-Synuclein	Lundbeck	Parkinson's disease	I
HuMab & DuoBody*			Partnered programs	Pre-Clinical

*Pipeline includes approx. 20 proprietary and partnered pre-clinical programs.

Innovation Powerhouse: Cutting Edge Proprietary Technologies

Technology		Principle	Applications
DuoBody		Bispecific antibodies	Dual targeting: - Recruitment (e.g. T cells) - Tumor heterogeneity
HexaBody		Target-mediated enhanced hexamerization	Enhanced potency: - CDC - Target clustering, outside-in signaling, apoptosis
DuoHexaBody		Bispecific antibodies with target-mediated enhanced hexamerization	Dual targeting + enhanced potency - CDC - Target clustering, outside-in signaling, apoptosis
HexElect		Two co-dependent antibodies with target-mediated enhanced hexamerization	Dual targeting + enhanced potency & selectivity: - Co-dependent unlocking of potency - New target space, previously inaccessible

Genmab's Commitment to Society

Corporate Social Responsibility (CSR)

Anchored in our Core Purpose & Vision

Focus on four main areas

- Employee well-being, including health, safety & development
- Ethics in relation to pre-clinical and clinical studies
- Environment, including waste management & recycling
- Business ethics & transparency

CSR Committee comprised of representatives from variety of functions

- Ensures that Genmab carries out CSR activities effectively & communicates clearly and openly

Tisotumab Vedotin

Cervical Cancer Market Size

United States[3]

New Diagnoses	Deaths
12,578	4,115

3rd most common gynecologic cancer in US[4]

Japan[6]

New Diagnoses	Deaths
9,390	3,654

2nd most common gynecologic cancer in Japan[6]

Europe[2]

New Diagnoses	Deaths
58,373	24,404

3rd most common gynecologic cancer in Europe[2*]

In developed countries, incidence rates are low (<7.9 per 100,000 women) compared with ***developing countries*** in sub-Saharan Africa and Central and South America, where incidence is especially high ***(>30 per 100,000 women)***[5]

*Europe is defined as the 40 countries in the four United Nations-defined areas of Europe and the European Union (EU-27).

References: 1. American Cancer Society **2.** .EUCAN (2012) **3.** Centers for Disease Control and Prevention. Cervical Cancer Statistics (2017) **4.** *UpToDate*. **5.** Ginsburg O et al. *Lancet* 2017 **6.** HPV Information Centre Japan (2017)

Ongoing Daratumumab Clinical Trials

Janssen Sponsored Phase III & IV

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier	Phase	Sponsor	Indication	Therapy
NCT03768960	IV	J&J Private Ltd	Relapsed or Refractory MM	Daratumumab (MMY4008)
NCT02252172	III	Janssen	Untreated MM	Daratumumab + Rd (MAIA)
NCT02195479	III	Janssen	Untreated MM	Daratumumab + VMP (ALCYONE)
NCT02541383	III	Janssen	Untreated MM	Daratumumab + VTd (CASSIOPEIA)
NCT02076009	III	Janssen	Relapsed or Refractory MM	Daratumumab + Rd (POLLUX)
NCT02136134	III	Janssen	Relapsed or Refractory MM	Daratumumab + Vd (CASTOR)
NCT03180736	III	Janssen	Relapsed or Refractory MM	Daratumumab + Pom-d (APOLLO)
NCT03201965	III	Janssen	Amyloidosis	Daratumumab + CyBorD (ANDROMEDA)
NCT03217812	III	Janssen	Untreated MM	Daratumumab + VMP (Asia Pacific) (OCTANS)
NCT03234972	III	Janssen	Relapsed or Refractory MM	Daratumumab + Vd vs Vd (China)
NCT03277105	III	Janssen	Relapsed or Refractory MM	Daratumumab SubQ vs IV (COLUMBA)
NCT03301220	III	Janssen	Smoldering MM	Daratumumab SC (AQUILA)
NCT03652064	III	Janssen	Untreated MM	Daratumumab + VRd (CEPHEUS)
NCT03710603	III	Janssen/EMN	Untreated MM	Daratumumab + RVd (PERSEUS)
NCT03901963	III	Janssen	Untreated MM / Maintenance	Daratumumab + R (AURIGA)

Ongoing Daratumumab Clinical Trials

Janssen Sponsored Phase I, I/II & II

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier	Phase	Sponsor	Indication	Therapy
NCT03384654	II	Janssen	Relapsed / Refractory ALL / LL	Dara + Vincristine + Prednisone + Doxorubicin (DELPHINUS)
NCT02951819	II	Janssen	Untreated and Relapsed MM	Daratumumab + CyBorD (LYRA)
NCT02874742	II	Janssen	Untreated MM	Daratumumab + RVd (GRIFFIN)
NCT02316106	II	Janssen	Smoldering MM	Monotherapy (CENTAURUS)
NCT02927925	II	Janssen	NKTCL, Nasal Type	Monotherapy (VOLANS)
NCT03412565	II	Janssen	Newly diag. & relapsed / refractory MM	Daratumumab SubQ + Rd, VMP & VRd (PLEIADES MMY2040)
NCT03871829	II	Janssen	Dara retreatment	Daratumumab SubQ+ Kd vs Kd
NCT01615029	I/II	Janssen	Relapsed and Refractory MM	Daratumumab + Rd (GEN503)
NCT02852837	I	Janssen	Relapsed or Refractory MM	Monotherapy (in China) (MMY1003)
NCT02519452	I	Janssen	Relapsed or Refractory MM	Monotherapy, subcutaneous (PAVO)
NCT02918331	I	Janssen	Untreated MM	Daratumumab + Rd (Japan) (MMY1006)
NCT03242889	I	Janssen	Relapsed or Refractory MM	Daratumumab subq (Japan) (MMY1008)
NCT01998971	I	Janssen	Various MM	Daratumumab + backbone regimens (Vd, VMP, VTd, Pom-d, Kd, KRd) (EQUULEUS)
NCT03320707	I	Janssen	Healthy volunteers	Daratumumab vs placebo (EDI1001)

Ongoing Daratumumab Clinical Trials

Other Industry Sponsored Trials

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier	Phase	Sponsor	Indication	Therapy
NCT03158688	III	Amgen	Relapsed or Refractory MM	Daratumumab + Kd (CANDOR)
NCT01946477	II	Celgene	Relapsed or Refractory MM	Daratumumab + Pom-d
NCT02807454	II	Celgene	Relapsed and Refractory MM	Daratumumab + Imfinzi (FUSION)
NCT03439293	II	Takeda	Relapsed or Refractory MM	Daratumumab + NINLARO (ixazomib) + Dex
NCT02773030	I/II	Celgene	Relapsed or Refractory MM	Daratumumab + CC-220 + Dex
NCT02343042	I/II	Karyopharm	Relapsed or Refractory MM	Daratumumab + Selinexor + Dex
NCT03481556	I/II	Oncopeptides AB	Relapsed or Refractory MM	Daratumumab + Melflufen + Dex
NCT01592370	I/II	BMS	Relapsed or Refractory MM	Daratumumab + nivolumab
NCT03837509	I/II	Incyte	Relapsed or Refractory MM	Daratumumab + INCB001158
NCT02431208	I	Roche	Resistant or Refractory MM	Daratumumab + Tecentriq (atezolizumab)
NCT03068351	I	Roche	Resistant or Refractory MM	Daratumumab + RO6870810
NCT04045028	I	Genentech	Relapsed or Refractory MM	Daratumumab + tiragolumab
NCT04136756	I	Nektar Thera.	Salvage for MM	Daratumumab + NKTR-255

As per clinicaltrials.gov, Nov 2019

www.genmab.com